Chiusura precedente | 25,58 |
Aperto | 25,45 |
Denaro | 25,74 x 100 |
Lettera | 25,97 x 100 |
Min-Max giorno | 25,45 - 25,75 |
Intervallo di 52 settimane | 16,54 - 28,13 |
Volume | |
Media Volume | 81.009 |
Capitalizzazione | 382,088M |
Beta (5 anni mensile) | 0,75 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -5,64 |
Prossima data utili | 08 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 30,33 |
BEDFORD, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2023 financial results after the close of the market on Thursday, November 2, 2023 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing 1-844-826-303
RevoMotion™ Reverse Shoulder System showing smallest diameter threaded glenoid baseplate RevoMotion™ Reverse Shoulder System showing smallest diameter threaded glenoid baseplate Integrity™ Implant System Integrity™ Implant System RevoMotion Reverse Shoulder Arthroplasty System significantly expands Anika’s shoulder arthroplasty portfolio and provides a bone conserving and innovative solution in the $1 billion1 U.S. reverse shoulder market RevoMotion adds to a growing, highly differentiated portf
BEDFORD, Mass., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on September 5, 2023, Anika granted restricted stock units ( “RSUs”) covering 10,000 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, was approved by the compensation committee of the board of directors pursuant to a